The endoplasmic reticulum (ER)-transmembrane proteins, ATF6␣ and ATF6␤, are cleaved during the ER stress response (ERSR). The resulting N-terminal fragments (N-ATF6␣ and N-ATF6␤) have conserved DNA-binding domains and divergent transcriptional activation domains. N-ATF6␣ and N-ATF6␤ translocate to the nucleus, bind to specific regulatory elements, and influence expression of ERSR genes, such as glucose-regulated protein 78 (GRP78), that contribute to resolving the ERSR, thus, enhancing cell viability. We previously showed that N-ATF6␣ is a rapidly degraded, strong transcriptional activator, whereas ␤ is a slowly degraded, weak activator. In this study we explored the molecular basis and functional impact of these isoform-specific characteristics in HeLa cells. Mutants in the transcriptional activation domain or DNA-binding domain of N-ATF6␣ exhibited loss of function and increased expression, the latter of which suggested decreased rates of degradation. Fusing N-ATF6␣ to the mutant estrogen receptor generated N-ATF6␣-MER, which, without tamoxifen exhibited loss-of-function and high expression, but in the presence of tamoxifen N-ATF6␣-MER exhibited gain-of-function and low expression. N-ATF6␤ conferred loss-of-function and high expression to N-ATF6␣, suggesting that ATF6␤ is an endogenous inhibitor of ATF6␣. In vitro DNA binding experiments showed that recombinant N-ATF6␤ inhibited the binding of recombinant N-ATF6␣ to an ERSR element from the GRP78 promoter. Moreover, siRNA-mediated knock-down of endogenous ATF6␤ increased GRP78 promoter activity and GRP78 gene expression, as well as augmenting cell viability. Thus, the relative levels of ATF6␣ and -␤, may contribute to regulating the strength and duration of ATF6-dependent ERSR gene induction and cell viability.
Stresses that alter the rough ER 3 environment can impair folding of proteins synthesized by this organelle (1) (2) (3) (4) . Numerous proteins induced under such conditions are targeted to the ER, where they aid in nascent protein folding and thus, counteract the stress; this ER-initiated signaling process is known as the ER stress response (ERSR). ERSR elements (ERSEs) are located in the regulatory regions of many ERSR genes. One of the transcription factors that mediates ERSR gene induction via ERSEs is ATF6␣, a 670-aa ER trans-membrane protein (5, 6) ( Fig. 1A, ATF6␣ ). ER stress activates the proteolytic cleavage of ϳ400 aa from the N terminus of ATF6␣ (N-ATF6␣) (7) , which translocates to the nucleus and activates numerous ERSR genes (8, 9) . The transcriptional activation domain (TAD) of N-ATF6␣ resides in the N-terminal portion of the protein, whereas the basic leucine zipper (b-Zip) and nuclear localization domains reside in the C terminus (Fig. 1B , N-ATF6␣) (8, 10) . N-ATF6␣ can bind directly to ATF6 binding sites (9) , or it can combine with several other proteins to form a complex that binds to ERSEs and augments the induction of numerous ERSGs, such as the ER chaperone, glucose-regulated protein 78 kDa (GRP78) (8, 9, (11) (12) (13) . N-ATF6␣ exhibits potent transcriptional activity, however, it is susceptible to proteasome-mediated degradation, and mutations in the TAD that reduce N-ATF6␣ transcriptional activity decrease degradation (14) . Several other potent transcription factors that exert rapid, transient effects exhibit similar coupling of transcriptional activation and degradation (15) , including the virally encoded protein, VP16 (16) . An 8-aa domain in VP16, called VN8, confers strong transcriptional activity and susceptibility to degradation, and mutations in VN8 that reduce VP16 activity decrease degradation (17, 18) . The TAD of ATF6␣ possesses a VN8-like sequence, and mutating it in ways known to decrease VP16 activity decrease ATF6␣ activity and degradation (14) . To the best of our knowledge, the VN8 domain has not been found in any other mammalian transcription factor, including a second isoform of ATF6, ATF6␤.
Like ATF6␣, ATF6␤ is an ER-transmembrane protein (Fig.  1A, ATF6␤ ), and during ER stress proteolysis generates an N-terminal fragment of ϳ400 aa (19) . N-ATF6␣ and N-ATF6␤ possess highly conserved b-Zip domains, which allow them to bind to ERSEs as homo-or heterodimers (20) ; however, the N-terminal regions are divergent. For example, the region of N-ATF6␤ corresponding to the VN8 of N-ATF6␣ differs in 5 of 8 aa in ways predicted from studies with VP16 to diminish transcriptional activity (21) (Fig. 1B, N-ATF6␤ ). In support of this prediction were findings that ectopically expressed N-ATF6␤ is a poor ERSR gene inducer (6) that exhibits much greater stability than N-ATF6␣ (14) . Accordingly, although they can bind to the same regulatory elements, N-ATF6␣ and -␤ exhibit isoform-specific transcriptional activation and stability characteristics. Thus, N-ATF6␣ and -␤ might function in a combinatorial fashion to fine-tune the strength of ERSR gene activation.
In the present study, we examined the molecular mechanism and function of the isoform-specific characteristics of N-ATF6␣ and -␤, addressing the following hypotheses: 1) the isoform-specific characteristics of N-ATF6␣ and -␤ are conferred by their divergent N-terminal TADs; 2) N-ATF6␣-mediated transcriptional activation and rapid degradation are coordinated processes, and 3) the relative levels of N-ATF6␣ and -␤ impact ERSR gene induction and cell viability in ways consistent with roles of N-ATF6␤ as a transcriptional repressor of N-ATF6␣.
EXPERIMENTAL PROCEDURES

Methods
Replicates and Statistical Analysis-Unless otherwise stated in the legends or figures, each treatment was performed on three identical cultures, and each experiment was repeated at least three times. Representative experiments are shown. Statistical analyses were performed using a one-way ANOVA followed by the StudentNewman-Keul post-hoc analysis. *, #, or § ϭ p Ͻ 0.05; **, ##, § §, or ᮍᮍ ϭ p Ͻ 0.01.
Cell Culture-HeLa Cells were maintained in Dulbecco's modified Eagle's medium containing 10% fetal calf serum. For transfection experiments, HeLa cells were resuspended at 5-9 ϫ 10 6 cells per 400 l of cold Dulbecco's phosphate-buffered saline and electroporated in a 0.4-cm gap electroporation cuvette at 250 V and 950 microfarads using a GenePulser II Electroporator (BioRad). The cells were then plated at a density of 0.5 ϫ 10 6 per 24-mm well for experiments involving luciferase and ␤-galactosidase enzyme assays, or 1.5 ϫ 10 6 per 35-mm well for experiments involving immunoblotting. Reporter assays and immunoblotting were carried out as previously described (22) .
Plasmids
CMV-Galactosidase-CMV-␤-galactosidase, which codes for a ␤-galactosidase reporter driven by the CMV promoter, was used to normalize for transfection efficiency.
N-ATF6␤-VN8 Mutations-Mutations were introduced into 3ϫ FLAG-ATF6␤-(1-392) to mimic the VN8 region of ATF6␣. Accordingly, the following changes were introduced into ATF6␤-VN8-M1: V65F, G66D, and M67L; whereas the following changes were introduced into ATF6␤-VN8-M2: V65F, G66D, M67L, V69L, and S70L. ATF6␤-VN8-M1 and ATF6␤-VN8-M2 were created by PCR, using QuikChange from Stratagene and the relevant primers required to introduce the desired amino acid substitutions.
N-ATF6␣ and N-ATF6␤ Chimeras-Constructs encoding chimeric proteins composed of various portions of N-ATF6␣ and -␤ were designed by aligning the sequences of N-ATF6␣ and -␤ and selecting homologous regions for domain swapping studies. Appropriate PCR fragments were generated from 3ϫ FLAG-N-ATF6␣ and -␤, so that an XhoI restriction site was introduced at the ATF6␣ and -␤ junction in each chimera. The amino acid sequence used to name each chimera refers to the original, full-length sequence of either ATF6␣ and -␤. The constructs generated are: ATF6␣-(1-114)/ATF6␤-(116 -392), ATF6␣-(1-180)/ATF6␤-(191-392), and ATF6␣-(1-302)/ ATF6␤-(322-392), which are named constructs 3, 4, and 5, respectively, in Fig. 3A . (6, 14, 19, 20, 22) . These forms of ATF6␣ and -␤, which are localized to the ER, exhibit conserved sequences in the basic, leucine-zipper (Leu-Zip) and ER transmembrane (ER TM) domains, but divergent sequences in the N-terminal transcriptional activation domains. ER stress stimulates the regulated intramembranous proteolysis (RIP) of both ATF6␣ and -␤ near and in the ER-transmembrane domains by the Golgi-associated proteases, S1P and S2P (7) . B, ATF6 after ER stress: The diagram depicts the N-terminal, "active" forms of ATF6␣ and -␤, which are called N-ATF6␣ and N-ATF6␤ in this study. Also shown are the eight amino acids comprising the VN8 region of ATF6␣, which is required for optimal transcriptional activity and degradation (14) . The homologous region between residues 64 and 71 of ATF6␤ is shown to emphasize the lack of the Phe and Leu that are required for activity in ATF6␣.
N-ATF6␣ and N-ATF6␤ Gal4 DBD Fusion Proteins-A construct encoding the Gal4 DBD fused to the N terminus of ATF6␣-(1-114) (i.e. Gal4 DBD-ATF6␣-(1-114)) was created by PCR, using 3ϫ FLAG-ATF6␣-(1-373) as the template, and the appropriate primers, to create an amplicon with a BamH1 site on the 5Ј-end, and a termination codon and SacI site on the 3Ј-end. This PCR product was then cloned into Gal4 DBD (pSG424, GenBank TM accession number X85976). Clones Gal4 DBD-M (L32P) and Gal4 DBD-M (L32P)-ATF6␣-(1-114) were generated using QuikChange from Stratagene and the appropriate primers.
N-ATF6␣-MER Fusion Protein-A PCR product composed of the nucleotides encoding aa 281-599 of the mouse mutated (G525R) estrogen receptor (MER, a gift from Dr. Michael Reth, Max-Plank-Institute, Freiburg, Germany) was cloned into the NotI/EcoR1 site of pCDNA3.1-3ϫ FLAG vector to create 3ϫ FLAG-MER. Subsequently, a PCR product of N-ATF6␣ was generated, which introduced a NotI site and removed the termination site after aa 373, was cloned into the XhoI/NotI site of 3ϫ FLAG-MER to create 3ϫ FLAG-N-ATF6␣-MER.
3ϫ HA-ATF6␤-3ϫ HA-ATF6␤ was generated by subcloning N-ATF6␤ from 3ϫ FLAG-N-ATF6␤ into pCDNA3.1-3ϫ HA, which has been described elsewhere (22) .
GRP78-Promoter-luc-Reporter constructs encoding the GRP78 promoter from Ϫ284 to ϩ7 or Ϫ284 to ϩ221 driving luciferase have been described elsewhere (23) .
Small Interfering RNAs
The use of small interfering (si) RNA targeted against human ATF6␣ and -␤ has been described elsewhere (22) . Briefly, HeLa cells were plated on 6-well plates at ϳ400 K cells per well, then transfected with 50 ng of the relevant dicer siRNAs, using Lipofectamine 2000 TM . After 24 h, cells were treated with or without tunicamycin (2 g/ml), and then examined by real-time quantitative PCR (see below), or, before tunicamycin treatment, they were removed from the plate with TripLE (Invitrogen), and re-plated in 96-well plates at ϳ10 K cells per well in preparation for viability assays. To examine viability, cells in 96-well plates were treated with or without tunicamycin (2 g/ml) and 2-deoxyglucose (3 mM) in serum-free media for 32 h. Cell viability was then assessed using an MTT Cell Proliferation Kit according to the manufacturer's protocol (Roche Applied Science). Samples were read at 570 nm in a VersaMax microplate reader (Molecular Devices, Downingtown, PA).
Real-time Quantitative PCR
HeLa cells were transfected with the appropriate siRNA, as described above, then after treatments, they were lysed and RNA was extracted using an RNeasy kit (Qiagen). cDNA was generated by reverse transcription using a Superscript III kit (Invitrogen). In N-ATF6␤-VN8-M1 (construct 3), residues 65-67 of N-ATF6␤ were mutated as follows: V65F, G66D, and M67L. In ATF6␤-VN8-M2 (construct 4), residues 69 and 70 of N-ATF6␤-VN8-M1 were mutated as follows: V69L and S70L. B, GRP78 promoter activity: HeLa cells were transfected with either an empty vector control (Con), or with one of the four constructs shown in A. Cells were co-transfected with either pGL2P, or GRP78-luciferase, and CMV-␤-galactosidase, plated, and 48 h later, extracted and analyzed for reporter enzyme activities, as described under "Methods." Rel Luciferase is the mean value for GRP78-luciferase/ ␤-galactosidase divided by pGL2P-luciferase/␤-galactosidase for each sample Ϯ S.E., n ϭ 3 cultures. Values for Con, construct 2 and 3, are in one group, and ** and § § ϭ p Ͻ 0.01 are different from all other values, as determined using ANOVA followed by Newman-Keuls post hoc analysis. C, FLAG immunoblot (IB): Extracts from the cultures described in B were analyzed by SDS-PAGE and immunoblotting for FLAG. Real-time quantitative PCR was performed on cDNA using the Quanti-Tect SYBR Green PCR kit (Qiagen) on an ABI Prism 7000 (Applied Biosystems, Foster City, CA). The relative abundance of GRP78 RNA was calculated using the ⌬⌬C t method, as previously described (24) . Primers (see below) were designed using primer express version 2.0 (Applied Biosystems). All primers were determined to be 90% to 110% efficient, and all exhibited only one dissociation peak as follows: GRP78: (ϩ) CCACCTCAGTCTCC-CAGCTAA; (Ϫ) GCCGAGCATGGTGGTAACA; ATF6␣: (ϩ) CACAGCTCCCTAATCACGTGG; (Ϫ) ACTGGGCTATTCG-CTGAAGG; ATF6␤: (ϩ) CAGCCATCAGCCACAACAAG; (Ϫ) GGCATCACCAGGGACATCTT; and glyceraldehyde-3-phosphate dehydrogenase: (ϩ) GCCACATCGCTCAGACACC; (Ϫ) CAAATCCGTTGACTCCGACC.
Electrophoretic Mobility Shift Assays
Electrophoretic mobility shift assays (EMSAs) were carried out essentially as previously described (25) . Double-stranded synthetic oligonucleotides were used as 32 P-labeled probes or competitors, as described in the figure legends. The GRP78 ERSE-1 sequence was: CCGGGAGGGCCTTCACCAATCG-GCGGCCTCCACGACGGGGCTGGC (underlined nucleotides are a consensus ERSE), and the GRP78 ERSE1 MM sequence was CCGGGAGGGCCTTCAgactaCGGCGGCCTgatgtACGG-GGCTGGC (mutated nucleotides indicated by lowercase). Nuclear extracts, which provide the source of other proteins (e.g. NF-Y, YY1, and TFII-I) needed for ATF6 binding to ERSEs, were prepared as previously described (25) . Binding reactions were carried out in a solution composed of 20 mM HEPES (pH 7.9), 10% glycerol, 1 mM MgCl 2 , 1 mM 2-mercaptoethanol, 0.1% Tween 20, 0.2 g of poly(dI-dC), 6 g of HeLa nuclear extract, 2 l of in vitro translated ATF6␣-(1-373), ATF6␣-(115-373), or ATF6␤-(1-392), prepared as previously described (10), and 10,000 cpm of 32 P-labeled probe. Reactions were incubated at room temperature for 20 min, and then fractionated on a 5% polyacrylamide gel at 200 V for 150 min in 0.5ϫ TBE buffer (45 mM Tris borate, 1 mM EDTA). For supershift EMSAs, 1 l of anti-ATF6␣ (Santa Cruz Biotechnology, sc-22799), 1 l of anti-ATF6␤ (Santa Cruz Biotechnology, sc-30596), or 1 l of non-immune mouse antisera was added 15 min prior to probe addition. For oligonucleotide specificity assessment, 250-fold excess of unlabeled double-stranded oligonucleotide was added 15 min prior to addition of probe.
RESULTS
Isoform-specific Characteristics of N-ATF6␣ and -␤ Are
Conferred by Their Divergent N-terminal TADs-Because we previously showed the importance of the VN8 sequence for . The boundary amino acids were selected based on sequence homology. B, GRP78 promoter activity: HeLa cells were co-transfected with either an empty vector control (Con), or the ATF6 expression constructs shown, and GRP78-luciferase or pGL2P and CMV-␤-galactosidase, as in Fig. 2 . After 48 h in culture, extracts were assayed for reporter enzyme activities, as described under "Methods." Mean Rel Luciferase Ϯ S.E., n ϭ 3 cultures is shown. Values for Con and construct 2 are in one group, § , p Ͻ 0.05 and **, p Ͻ 0.01 are different from all other values, as determined using ANOVA followed by Newman-Keuls post hoc analysis. C, FLAG immunoblot (IB): extracts from the cultures described in B were analyzed by SDS-PAGE and immunoblotting for FLAG. Constructs 1-5 refer to the same constructs shown in A. The mean relative expression levels of each expression protein Ϯ S.E. are shown at the top of each gel. D, GRP78 promoter activity normalized to protein levels: The mean Rel Luciferase values from B were divided by the mean expression levels of each protein from C, to generate the specific activity. Values for Con and constructs 2 and 3 are in one group, ##, § §, and ** ϭ p Ͻ 0.01 are different from all other values, as determined using ANOVA followed by Newman-Keuls post hoc analysis. , and R315A, as previously described (9) . Construct 3 encodes the native Gal4 DBD, whereas construct 4 encodes Gal4 DBD-M with a DNA-binding domain mutation, L32P. Construct 5 encodes native Gal4 DBD fused to the N terminus of ATF6␣-(1-114), whereas construct 6 encodes the same Gal 4 DBD-M fused to the N terminus of ATF6␣- (1-114) . B, GRP78 luciferase or Gal4 luciferase: HeLa cells were transfected with the constructs shown (Con ϭ empty vector), and either GRP78-luciferase, or Gal4-luciferase, and after 48 h in culture, extracts were assayed for reporter enzyme activities, as described under "Methods." Rel Luciferase ϭ GRP78-luciferase/␤-galactosidase, or Gal4-luciferase/␤-galactosidase. Shown are mean Rel Luciferase values Ϯ S.E. (n ϭ 3 cultures). In the GRP78-Luc panel, values for Con and construct 2 are in one group, and in the Gal4-Luc panel, constructs 3, 4, and 6 are in one group. For both panels, **, p Ͻ 0.01 are different from all other values in that panel, as determined using ANOVA followed by Newman-Keuls post hoc analysis. C, FLAG and Gal4 DBD immunoblots (IB): extracts from the cultures described in B were analyzed by SDS-PAGE and immunoblotting for FLAG or Gal4, as shown. Constructs 1-6 refer to the same constructs shown in A. All lanes were loaded with 30 g of protein, except those for construct 3, which were loaded with 3 g. The mean relative expression levels Ϯ S.E. are shown at the top of each gel.
the transcriptional activity and rapid degradation of ATF6␣ (22), we assessed whether the lack of a VN8 sequence in ATF6␤ is responsible for its low transcriptional activity and high stability. Upon sequence alignment of N-ATF6␣ and -␤, we found that residues 64 -71 of ␤ correspond to residues 61-68 of ␣, the VN8-like region (Fig. 1B) . Accordingly, residues 64 -67 of N-ATF6␤ (i.e. ATF6␤-(1-392)) were mutated to the same residues found in the VN8-like region of ATF6␣, which possess the Phe and Leu known to be required for optimal activity ( Fig. 2A, construct 3 , ATF6␤-VN8-M1). We also prepared a mutation that converted the entire 64 -71 region N-ATF6␤ to be identical to the VN8 in ATF6␣ (Fig.  2A, construct 4 , ATF6␤-VN8-M2). The abilities of native N-ATF6␤ or the VN8 mutations to activate the promoter of the prototypical ERSR gene, GRP78, in HeLa cells were compared with N-ATF6␣ (i.e. ATF6␣-(1-373)). As previously seen (22) , N-ATF6␣ exerted strong GRP78 promoter activation, whereas native N-ATF6␤ exhibited weak effects (Fig. 2B, constructs 1  versus 2) . Among the ATF6␤ VN8 mutations, only ATF6␤-VN8-M2 exhibited detectible GRP78 promoter activation, although it amounted to only ϳ8% of N-ATF6␣ (Fig. 2B, construct 4) . Previous studies showed that the relative levels of ectopically expressed ATF6␣ and -␤ are proportional to their half-lives (22) . N-ATF6␣ was expressed in very low quantities (Fig. 2C, construct 1) , consistent with its known short half-life, whereas all forms of N-ATF6␤ were expressed at much higher levels (Fig. 2C, constructs  2-4) , suggesting that they exhibited relatively long half-lives, as previously shown for native N-ATF6␤ (22) . Quantification demonstrated that N-ATF6␤, N-ATF6␤-VN8-M1, and N-ATF6␤-VN8-M2 were expressed at ϳ40-, 29-, and 20-fold higher levels than N-ATF6␣, respectively (Fig. 2C) . Thus, although their expression levels and apparent half-lives decreased in coordination with the minor increases in activity, it was apparent that the low transcriptional activity and high stability of N-ATF6␤ were not due entirely to the lack of a consensus VN8 sequence, but that larger portions of ATF6␤ must be required to confer these isoform-specific characteristics.
To examine the effects of mutating larger portions of ATF6␣ and -␤, a series of domain-swap mutations were generated where the N terminus of N-ATF6␤ was replaced with progressively larger portions of the corresponding sequences from N-ATF6␣ (Fig. 3A) . As expected, native N-ATF6␣ was a strong activator of the GRP78 promoter, whereas native N-ATF6␤ was much weaker (Fig. 3B, constructs 1 versus 2) . However, when the N-terminal 115 or 190 aa of N-ATF6␤ were replaced with corresponding sequences from ␣, transcriptional activity increased progressively (Fig.  3B, constructs 3 and 4) . Finally, when the N-terminal 321 aa of N-ATF6␤, representing all but the 71-aa b-Zip domain, were replaced by corresponding sequences from N-ATF6␣, GRP78 promoter activity increased to about the same level as that observed using native N-ATF6␣ (Fig. 3B, construct 5) , suggesting that the b-Zip domains of N-ATF6␣ and -␤ were interchangeable. As expected, the level of expression of N-ATF6␤ was ϳ80-fold greater than N-ATF6␣ (Fig. 3C, constructs 1 and 2) ; moreover, expression levels of the chimeras declined coordinately as more sequences from N-ATF6␣ replaced corresponding sequences in ␤ (Fig. 3C , constructs [3] [4] [5] , consistent with the hypothesis that the degradation rate of ATF6 coordinates with its transcriptional activity. When GRP78 promoter activity was normalized to the levels of ectopic N-ATF6␣ or -␤ protein expression, the only domain-swap mutant exhibiting activity approximating that of native N-ATF6␣ was construct 5 (Fig. 3D) . Accordingly, these data suggested that, although the b-Zip domain of ATF6␤ can substitute for the b-Zip domain of ATF6␣ without much loss of function, most of the sequences lying to the N terminus of the b-Zip domain of ATF6␣ are necessary to confer the full transcriptional activity and rapid degradation characteristic of this ATF6 isoform.
N-ATF6␣-mediated Transcriptional Activation and Rapid Degradation Are Coordinated Processes-It is not known whether it is the sequences in the TAD of ATF6␣ that confer strong transcriptional activation and rapid degradation, or whether rapid degradation is a function of the engagement of ATF6␣ in a productive transcription complex. If the latter is true, then mutating the basic region of the b-Zip domain to disrupt binding of N-ATF6␣ to ERSEs should decrease transcriptional activation and decrease degradation. Consistent with this hypothesis was our finding that mutating the basic region of N-ATF6␣ (Fig. 4A, construct 2) to disrupt the binding of N-ATF6␣ to ERSEs (9) resulted in decreased GRP78 promoter activation (Fig. 4B, constructs 1 and 2 ) and increased N-ATF6␣ expression of Ͼ3-fold (Fig. 4C, FLAG   blot, constructs 1 and 2) . To test this hypothesis in a heterologous gene expression system, we used a truncated form of the yeast transcription factor Gal4, Gal4-(1-147), composed of the Gal4 DBD, which does not possess a TAD. The binding of the Gal4 DBD to appropriate DNA sequences was assessed using a luciferase reporter driven by a neutral promoter flanked by tandem repeats of the Gal4 binding element. A mutation known to block the binding of Gal4-(1-147) to the Gal4 binding element (26) was introduced into a construct featuring the TAD of ATF6␣ without the ATF6 DBD, i.e. ATF6␣- (1-114) , fused to the Gal4 DBD (Fig. 4A, constructs 5  and 6 ). As expected, the ATF6␣(1-114)/Gal4 DBD fusion protein without the DBD mutation exhibited robust transcriptional activation, compared with the Gal4 DBD alone (Fig. 4B, constructs 3 and 5) ; however, the ATF6␣(1-114)/ Gal4 DBD fusion protein harboring the DBD mutation exhibited no transcriptional activation (Fig. 4B, construct 6) . Moreover, the level of expression of ATF6␣/Gal4 DBD-M was ϳ2-fold greater than that of ATF6␣/Gal4 DBD (Fig. 4C , Gal4 blot, constructs 5 and 6), whereas the level of expression of Gal4 DBD-M was actually somewhat lower than that of Gal4 DBD (Fig. 4C, Gal4 blot, constructs 3 and 4) . These results are consistent with the hypothesis that rapid degradation of N-ATF6␣ requires its engagement in transcriptional activation.
To examine the relationship between transcriptional engagement and ATF6 degradation in a different model system, we designed a method for conditionally activating N-ATF6␣ in a ligand-dependent manner. For this purpose, we generated a construct encoding N-ATF6␣ fused to a fragment of the MER, which has no TAD or DBD, but features a tamoxifen-ligand-binding domain replacing the estrogenbinding domain. By analogy to the way MER affects other proteins to which is has been fused (27), we reasoned that, in the absence of tamoxifen, the MER would attract other cellular components, e.g. HSP90, which would block functional domains of ATF6, but that, upon tamoxifen binding, release of HSP90, among others, would reveal functional domains and allow full engagement of ATF6 in transcription (Fig. 5A) . Accordingly, constructs encoding FLAG-MER or FLAG-N-ATF6␣-MER, where MER is fused to the C terminus of FLAG-N-ATF6␣, were prepared (Fig. 5B) , and the abilities of each to activate the GRP78 promoter were examined. As expected, FLAG-MER exhibited essentially no activity (Fig.  5C, construct 1) , whereas FLAG-N-ATF6␣ exhibited high activity that was affected very little by tamoxifen (Fig. 5C,  construct 3) . In contrast, FLAG-N-ATF6␣-MER exhibited FIGURE 5. Effect of tamoxifen on ATF6␣-MER chimera. A, diagram of MER mechanism of action: the diagram (36) depicts the putative mechanism of action of ATF6␣ fused to a fragment of the mutant mouse estrogen receptor (MER). The construct encodes FLAG-ATF6␣ with the MER fused to the C terminus. In the absence of ligand (i.e. tamoxifen, TX), various cellular proteins, e.g. HSP90, bind to the MER and mask the function domains of ATF6. Addition of tamoxifen to cultures expressing FLAG-N-ATF6␣-MER leads to displacement of HSP90, among others, unmasking of ATF6 functional domains, and activation of ATF6␣-dependent transcription. B, diagram of constructs: constructs 1-3 were generated so they encode FLAG with MER fused to the C terminus of FLAG (construct 1), FLAG-N-ATF6␣ with MER fused to the C terminus of N-ATF6␣ (construct 2), or FLAG-N-ATF6␣ (construct 3). C, effect of tamoxifen on GRP78-Luciferase: HeLa cells were transfected with constructs 1-3 along with GRP78-Luciferase and CMV-␤-galactosidase. Cultures were then treated with or without tamoxifen (TX) 5 M, and after 16 h, extracts were prepared and assayed for reporter enzyme activities, as described under "Methods." Mean Rel Luciferase Ϯ S.E., n ϭ 3 cultures is shown. The values for construct 1 with or without TX are in one group, whereas **, ##, § §, or ᮍᮍ ϭ p Ͻ 0.01 are different from all other values, as determined using ANOVA followed by Newman-Keuls post hoc analysis. D, effect of tamoxifen on N-ATF6␣-MER expression: HeLa cells were transfected with constructs 1-3, treated with or without tamoxifen (TX), as described in B, and after 48 h, extracts were fractionated by SDS-PAGE followed by FLAG immunoblotting. little activity in the absence of tamoxifen, but, upon tamoxifen addition, activity increased 3-fold, nearly equal to that of FLAG-N-ATF6␣ (Fig. 5C, construct 2) . The protein levels of FLAG-MER were relatively high in the absence of tamoxifen (Fig. 5D, lanes 1 and 2) , and actually increased by 1.6-fold in the presence of tamoxifen (Fig. 5D, lanes 3 and 4) , which was somewhat expected, because tamoxifen stabilizes MER. The levels of FLAG-N-ATF6␣ were low and unchanged by tamoxifen (Fig. 5D, lanes 9 -12) . However, the levels of FLAG-N-ATF6␣-MER were decreased by ϳ5-fold in tamoxifen-treated cells (Fig. 5D, lanes 5-8) , suggesting coordination of tamoxifen-activated transcription and rapid degradation of FLAG-ATF6␣-MER.
Relative Levels of N-ATF6␣ and -␤ Impact ERSR Gene Induction and Cell Viability in Ways Consistent with Roles of N-ATF6␤ as a Transcriptional Repressor of N-ATF6␣-The
ATF6␣ loss-of-function mutations in this and previous studies exhibit decreases in degradation. We previously showed that N-ATF6␤ mimicked ATF6␣ loss-of-function mutations in terms of inhibiting N-ATF6␣-mediated transcription (22) , but its effect on ATF6␣ expression level and degradation is not known. Accordingly, a construct encoding FLAG-N-ATF6␣ was used to distinguish it from HA-N-ATF6␤ on immunoblots, and the ratios of ectopically expressed FLAG-N-ATF6␣ and HA-N-ATF6␤ were varied by transfecting HeLa cells with different amounts of the appropriate plasmids.
In the first series of experiments, the level of FLAG-N-ATF6␣-encoding plasmid was held constant, while the level of the HA-N-ATF6␤-encoding plasmid was varied. As expected, GRP78 promoter activation by FLAG-N-ATF6␣ was inhibited as the level of HA-N-ATF6␤ was increased (Fig. 6A, transfections 1-3 ). FLAG and HA immunoblots showed that the quantity of HA-N-ATF6␤ increased as a function of increased plasmid, as expected (Fig. 6B , HA-ATF6␤); interestingly, the levels of FLAG-N-ATF6␣ also increased, even though each culture had been transfected with the same quantity of the FLAG-N-ATF6␣ plasmid (Fig. 6B, FLAG-ATF6␣ ). These results suggested that HA-N-ATF6␤ not only inhibited the ability of FLAG-N-ATF6␣ to activate the GRP78 promoter, but also increased its half-life. We examined degradation of FLAG-N-ATF6␣ using cycloheximide (CHX) to inhibit new protein synthesis, as previously described (28) . The apparent degradation of FLAG-N-ATF6␣ was extremely rapid when no HA-N-ATF6␤ was co-expressed. Within 9 min of CHX addition, only 12% of the FLAG-N-ATF6␣ originally present remained (Fig. 6C, transfection 1, Blot A, versus transfection 1, Blot B) . In contrast, the degradation rate of FLAG-N-ATF6␣ was reduced in the presence of HA-N-ATF6␤; moreover, as the level of HA-N-ATF6␤ was increased, degradation rate of FLAG-N-ATF6␣ decreased. For example, at intermediate or high levels of HA-FLAG-N-ATF6␤, 66 and 82% of the original FLAG-N-ATF6␣ remained after 9 min of CHX treatment (Fig. 6C, transfections 2 and 3, Blot A versus Blot B) .
In the second series of experiments, the FLAG-N-ATF6␣-encoding plasmid was varied, while the HA-N-ATF6␤-encoding plasmid was held constant. As expected, HA-N-ATF6␤ alone conferred very little GRP78 promoter activation (Fig. 6D,  transfection 4) , whereas, increasing the levels of FLAG-N-ATF6␣ increased GRP78 promoter activity (Fig. 6D, transfections 5 and 6 ). FLAG and HA immunoblots showed that the level of FLAG-N-ATF6␣ increased as more plasmid was transfected, as expected (Fig. 6E, FLAG-ATF6␣, transfections 4 -6) ; however, surprisingly, the levels of HA-N-ATF6␤ decreased, even though each culture had been transfected with the same quantity of that plasmid (Fig. 6E, HA-ATF6␤, transfections 5  and 6 ). These results suggested that FLAG-N-ATF6␣ can increase the degradation rate of HA-N-ATF6␤. Consistent with this hypothesis was the finding that, in the absence of FLAG-N-ATF6␣, ϳ58% of the original HA-N-ATF6␤ was still present following 17 min of CHX treatment (Fig. 6F, transfection 4, Blot  A versus B) . In contrast, the degradation rate of HA-N-ATF6␤ was increased in the presence of FLAG-N-ATF6␣; moreover, as FLAG-N-ATF6␣ was increased, the degradation rate of HA-N-ATF6␤ increased. For example, at intermediate and high levels of FLAG-N-ATF6␣, 32 and 26% of the original HA-N-ATF6␤ was still present 17 min after CHX treatment (Fig. 6F , transfections 5 and 6, Blot A versus B). Taken together, the results of the experiments shown in Fig. 6 indicate that ATF6␣ and -␤ can influence each other, such that the isoform-specific transcriptional and degradation characteristics of each are dependent upon their relative levels. This finding is consistent with a mechanism whereby N-ATF6␣ and -␤ can regulate ERSR gene expression and cellular function in a combinatorial fashion.
Because ATF6␣ and -␤ can both bind to ERSEs (20) , EMSAs were performed to assess the abilities of recombinant ATF6␣ and -␤ to compete for binding to an ERSE in the GRP78 gene. Incubation of nuclear extract from untreated HeLa cells with a labeled oligonucleotide that replicates ERSE-1 in the GRP78 gene resulted in the formation of complex 1 (Fig. 7A, lane 1) . Formation of complex 1 has previously been shown to be due to binding of other nuclear proteins (e.g. NF-Y A, B, and C) to the ERSE in the absence of ATF6 (25) . Adding recombinant ATF6␣-(1-373) or ATF6␤-(1-392) to the nuclear extract resulted in the formation of complexes 3 and 4, respectively, which migrated with relative mobilities consistent with the sizes of each form of ATF6 that was added (Fig. 7A, lanes 2 and  3) . Adding a shortened form of ATF6, ATF6␣-(115-373), which should retain ERSE-binding ability, also exhibited a complex, complex 2, the mobility of which was consistent with the size of ATF6␣-(115-373) relative to the other forms of ATF6 used in this analysis (Fig. 7A, lane 4) . When an excess of unlabeled wild-type GRP78 ERSE-1 oligonucleotide was added to the incubation, all of the complexes disappeared (Fig. 7A, lanes  5-8) , as expected. However, excess unlabeled mutated GRP78 ERSE-1 was unable to compete for labeled oligonucleotide binding (Fig. 7A, lanes 9 -12) . These results demonstrate the dependence of each complex on the presence of the native GRP78 ERSE-1.
To verify the presence of ATF6 isoforms in complexes 2-4, supershift EMSA experiments were carried out. Addition of preimmune antiserum to the nuclear extract did not alter the EMSA profile (Fig. 7B, lanes 1-4) . However, addition of an antiserum specific for ATF6␣ altered the mobility of com-plexes 2 and 3, only (Fig. 7B , compare lanes 6 and 8 to lanes 2 and 4, respectively), whereas addition of an antiserum specific for ATF6␤ altered the mobility of complex 4, only (Fig. 7B, compare lane 11  with lane 3) . These results verify that complex 1 does not contain either form of ATF6, whereas complexes 2-4 contain ATF6␣-(115-373), ATF6␣-(1-373), and ATF6␤-(1-392), respectively.
Additional EMSAs were performed to determine the effects of ATF6␣ and ATF6␤ together on complex formation. Addition of ATF6␣-(1-373) and ATF6␤-(1-392) resulted in a decrease in the intensities of complexes 3 and 4 (Fig. 7C, compare lanes 2 and 3 to  lane 4) . Moreover, adding ATF6␣-(115-373) and ATF6␤-(1-392) demonstrated a decrease in the intensities of complexes 2 and 4 (Fig. 7C, compare lanes 7 to lanes 5  and 6) . Taken together, the results of the EMSA studies shown in Fig. 7 support the hypothesis that ATF6␣ and -␤ compete for binding to the canonical ERSE-1 in the GRP78 gene.
To examine the cellular effects of altering the relative levels of endogenous ATF6␣ and -␤, we used an siRNA approach that was previously shown by immunoblotting to selectively reduce the quantity of each ATF6 isoform in HeLa cells (22) . The selectivity of the siRNA reagents was verified here by quantitative reverse transcription-PCR assessment of ATF6␣ and -␤ mRNA in extracts from cells treated with siRNA targeted to green fluorescent protein (control), ATF6␣, ATF6␤, or another ERSR gene that is not the focus of this study, XBP1. Validating the specificity of the siRNAs was the finding that the ATF6␣-targeted siRNA reagent decreased the level of ATF6␣ and not ATF6␤ or XBP1 mRNA (Fig. 8A) , whereas the ATF6␤-targeted siRNA decreased the level of ATF6␤ and not ATF6␣ or XBP1 mRNA (Fig. 8B) . Knocking down ATF6␣ decreased basal and tunicamycin (TM)-stimulated GRP78 promoter activity by ϳ2-to 3-fold (Fig. 9A, bars 1  versus 2 and 4 versus 5) . In contrast, knocking down endogenous ATF6␤ had little effect on basal GRP78 promoter activity, but it increased TM-induced GRP78 luciferase by 2-fold (Fig. 9A, bars 4 versus 6) . Coordinate with these results were the findings that knockdown of ATF6␣ decreased TM-induced GRP78 mRNA by ϳ2-fold (Fig. 9B,  bar 4 versus 5) , whereas knockdown of ATF6␤ increased TM-induced GRP78 mRNA by ϳ1.5-fold (Fig. 9B, bar 6) . Because many ERSR genes, including GRP78, encode proteins that foster protection, we examined the effects of knocking down endogenous ATF6␣ or -␤ on HeLa cell viability. We found that, although 32 h of TM treatment conferred no change in viability in cells treated with control siRNA ( Fig. 9C; bars 1 versus 4) , knockdown of ATF6␣ significantly decreased viability with or without TM ( Fig. 9C ; bars 1 versus 2, and 4 versus 5), although knockdown of ATF6␤ significantly increased viability with or without TM ( Fig. 9C ; bars 1 versus 3 and 4 versus 6). These findings indicate that the isoform-specific characteristics of ATF6␣ and -␤ can influence TM-stimulated GRP78 expression, as well as viability of HeLa cells in ways that are consistent with the protective aspects of N-ATF6␣ and the putative abilities of N-ATF6␤ to serve as an endogenous repressor of ATF6␣. Moreover, because knocking down ATF6␣ or ␤ altered viability-TM, it is apparent that even in the absence of TMmediated ER stress, ERSR genes, such as GRP78, must contribute to cell viability.
DISCUSSION
In this study we examined the structural features underlying the isoform-specific characteristics of ATF6␣ and -␤, the coordination and mechanism of ATF6␣ transcriptional activation and rapid degradation, and whether the relative levels of ATF6␣ and -␤ affect their binding to ERSEs and regulate ERSR gene induction and cell viability. Our findings showed that there is structural information spanning most of the N-terminal 300 aa of ATF6␣ and -␤ that is required for isoform-specific characteristics. We also found that the rapid degradation of ATF6␣ is coordinate with its engagement in an active transcription complex, the latter of which can evidently be modulated by ATF6␤. Lastly, we determined the ratio of ATF6␣ and -␤ that modulates ERSR gene induction, as well as cell viability, in a manner consistent with the hypothesis that ATF6␣ is a strong but labile transcriptional activator, whereas ATF6␤ is a weak, stable transcriptional activator.
In addition to transcriptional activity and the rate of degradation, the timing of ATF6␣ and -␤ activation following ER stress is likely to be another important, albeit, not thor- FIGURE 7 . EMSAs examining the competition of ATF6␣ and ATF6␤ for binding to the GRP78 ERSE. A, oligonucleotide competition: EMSA analysis was carried out as described under "Methods." Recombinant ATF6␣-(1-373), ATF6␣-(115-373) or -␤-(1-392), used in the analyses shown in lanes 2-4, 6 -8, and 10 -12, respectively, were prepared by in vitro transcription/translation and then added to HeLa cell nuclear extracts. The 32 P-labeled GRP78 ERSE-1 probe was added to initiate the binding reactions. Complex 1 has been shown to be to the direct binding of nuclear extract-derived proteins, e.g. NF-Y, YY1, etc., to the ERSE. Under these experimental conditions, the binding of these accessory proteins is required before ATF6 will bind. Unlabeled double-stranded oligonucleotides representing the native GRP78 EMSA-1, or the mutated GRP78 EMSA-1 (MM) were added to lanes 5-8 and 9 -12, respectively. B, supershift: EMSA was carried out as described in A, lanes 1-4, except for the addition of either pre-immune, ATF6␣, or ATF6␤ antisera to lanes 1-4, 5-8, or 9 -12 , respectively. C, ATF6␣/␤ competition: EMSA was carried out as described in A, except for the addition of recombinant ATF6␣ and -␤ together with nuclear extracts in lanes 4, 7, 11 A, ATF6␣ mRNA: cultures were transfected with siRNA targeted against green fluorescent protein (GFP), ATF6␣, ATF6␤, or XBP1; 48 h later, cell extracts were analyzed for ATF6␣ mRNA by quantitative reverse transcription-PCR, as described under "Methods." Mean mRNA levels (% of maximum) Ϯ S.E., n ϭ 3 cultures are shown. *, p Ͻ 0.05 are different from all other values, as determined using ANOVA followed by Newman-Keuls post hoc analysis. B, ATF6␤ mRNA: cultures were transfected with siRNA and extracted as described in A, except ATF6␤ mRNA levels were assessed by quantitative reverse transcription-PCR, as described under "Methods." Mean mRNA levels (% of maximum) Ϯ S.E., n ϭ 3 cultures are shown. *, p Ͻ 0.05 are different from all other values, as determined using ANOVA followed by Newman-Keuls post hoc analysis. GFP-targeted siRNA was used as a control for an siRNA targeted to a non-expressed protein, and XBP1-targeted siRNA was used as a control to show that targeting a non-ATF6-related transcript did not affect the levels of ATF6␣ or -␤ mRNA.
oughly studied isoform-specific characteristic. Although it is well known that both ATF6 isoforms are cleaved upon ER stress, to our knowledge, only one study showed that, depending on the stress, activation of ATF6␣ can occur earlier than that of ATF6␤ (19) . Combined with their isoformspecific characteristics, sequential activation of the ATF6 isoforms (Fig. 10A) is consistent with the possibility that their relative levels could change as a function of time after ER stress, such that there is an initial, strong activation of ATF6-mediated ERSR gene induction, followed by modulation toward weak activation (Fig. 10B) . One potential mechanism by which ATF6␣ and -␤ could regulate the strength of ER stress involves how these isoforms bind to ERSR genes. ATF6␣ and -␤ bind to ERSEs, and possibly other elements, as dimers, which, interact with the C subunit of the NF-Y A, B, and C trimer (19) , as well as with other proteins, e.g. SRF (5), TFII-I (12), and perhaps YY1 (13) . Together, these proteins evidently facilitate ERSR gene induction. Thus, it is conceivable that, as a result of isoform-specific rates of generation and degradation, the relative levels of ATF6␣ and -␤ in transcriptional complexes change during progression of the ERSR and that, as a result of differences in their transcriptional activities, ERSR gene induction is finely tuned, as shown in Fig. 10C . The results of the gel shift experiments in this study showed that ATF6␣ and -␤ can compete with each other for binding to the GRP78 ERSE (Fig. 7C) , which lends further support to this hypothesis.
The mechanism governing the rate of degradation of ATF6 during transcription is not known. However, a great deal is known about the coupling of transcriptional activation and rapid degradation of other labile transcription factors, e.g. c-Myc, Gal4, VP16, SMAD2, STAT, and Hac1p (29) . In those cases, the most active transcription factors are also very susceptible to ubiquitination and proteasome-mediated degradation, both of which evidently take place during engagement in transcription (15, 30) . This "unstable when active" phenomenon is thought to allow tight control over transcription by ensuring that the activation of target genes is linked to the ongoing synthesis of the transcriptional regulator (30) . Accordingly, such transcription factors are usually potent target gene activators, which must effect their function in a transient manner, although, rapid degradation of transcription factors has been linked to modulation as well as augmentation of activity (31, 32) . Because ubiquitinligase/proteasome machinery exists in the nucleus and is FIGURE 9. Effect of ATF6␣ or -␤ siRNA on GRP78 induction and cell viability. A, GRP78-Luciferase: HeLa cells were transfected with GRP78-luciferase, CMV-␤-galactosidase, and the siRNA shown, and then treated with or without tunicamycin (2 g/ml) for 32 h. Cell extracts were then analyzed for reporter enzyme activities, as described under "Methods." Values shown are mean Ϯ S.E. (n ϭ 3). All-TM values are in one group, whereas **, ##, and § § ϭ p Ͻ 0.01 are different from all other values, as determined using ANOVA followed by Newman-Keuls post hoc analysis. B, GRP78 mRNA: HeLa cells were treated as in A, except they were not transfected with reporter enzymes, and RNA was extracted. Values shown are mean Ϯ S.E. (n ϭ 3). All -TM are in one group, while **, ##, and § § ϭ p Ͻ 0.01 are different from all other values, as determined using ANOVA followed by Newman-Keuls post hoc analysis. C, Viability: Hela cells were treated as in B, except after siRNA transfection, they were transferred into 96-well plates, treated with or without TM (2 g/ml) in 3 mM 2-doxyglucose (2-DG) for 32 h, then cell viability was determined, as described under "Methods." Values shown are mean Ϯ S.E. (n ϭ 3). **, ##, and § § ϭ p Ͻ 0.01 are different from all other values, as determined using ANOVA followed by Newman-Keuls post hoc analysis.
